2025 Q4 -tulosraportti
Vain PDF
125 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·9 min sitten · MuokattuYou're not the only one wondering what's coming in H1. Took a look at the ASGCT poster from May 2026 (see website) and see that in the last "box" "Conclusions" it states that in vivo studies of therapeutic potential in AAV9-circVec in 2 heart diseases were ongoing then. Danon disease which they started with in autumn 2025 and in Arrhythmogenic cardiomyopathy (ACM) is a rare, hereditary heart muscle disease where normal heart cells gradually die out and are replaced by scar tissue (fibrosis) and fat. The patient potential in the latter disease is large - estimated between 1.6 and 8 million patients. Imagine a treatment price of 1 million per patient and 250,000 patients gives revenue for this one disease alone of 250,000,000,000. Do you see the potential with circVec? New data from these projects should be expected in H1.- ·3 t sitten · MuokattuThe world's first company with clinical trials in circular RNA was RiboX - started not long ago. Synthetic circularRNA (like Orna and Orbital etc.) - not DNA based like CircVec. They recently failed. A patient with an autoimmune disease has died after receiving an experimental genetic medicine from a biotech startup in China, Endpoints News has learned. The Shanghai-based company, RiboX Therapeutics, recently received a green light from the FDA to begin a clinical trial of the treatment in the US, which the company announced on Aug. 8. But RiboX did not publicly disclose the death in the earlier study until questioned by Endpoints
Super important for Circio! It automatically puts more pressure on Big Pharmas, which now indirectly must prioritize low dose/low toxicity even more. - Which Circio has, hello? 🥳💰 
·4 t sittenI must say I'm really looking forward to the end of the month and the webcast. Circio and Wiklund have consistently impressed me with what is being presented. I believe and hope many will regret not buying more while they had the chance, but most of all, I think we can feel sorry for those who have sold out. Lots of luck to everyone! This will be an exciting period.
- ·4 t sitten · MuokattuA bit of CAR-T material from LinkedIn to shorten the waiting time and until we get CAR-T news going forward. The next 12-24 months will be important, he says. We know Circio is in the field but not acquired yet - the best trotters get a handicap - it's not important to be first at the start but to learn where others fail - the most important thing is to be best in the end. Cesare Di Nitto BD Manager @ Crystal NAX | Helped 200+ Biotech & Pharma advancing mRNA/LNP Programs | PhD Immuno-Oncology | Health, Fitness & Longevity 7 potential acquisitions. $17B+ committed. In vivo CAR-T is now a validated investment theme. We have seen it all: 1. AstraZeneca buying EsoBiotec ($1B, lentiviral ENaBL platform). 2. AbbVie taking Capstan Therapeutics ($2.1B, mRNA-LNP, Phase 1). 3. Gilead/Kite picked up Interius BioTherapeutics ($350M, integrating lentiviral vectors). 4. Bristol Myers Squibb grabbed Orbital Therapeutics ($1.5B for its circular RNA-LNP platform). 5. Eli Lilly and Company acquired Orna Therapeutics 1st ($2.4B, circRNA PAN-CAR LNP) 6. and Kelonia Therapeutics 2nd ($3.25B upfront, $7B total) 7. finally the recent Johnson & Johnson move to potentially acquire Sail Biomedicines ($785M upfront plus a $2.58B exclusive option, circRNA-tLNP). Pharma has made its conviction clear. But conviction isn't the same as clinical proof. The next 12-24 months will sort out who actually cracked it. Three things will separate the winners: • Safety Profile (MTD, toxicity): Genomic insertion is the risk RNA-LNP simply doesn't take on. No insertional mutagenesis. No long-term genotoxicity. LVV platforms carry both, and can hit MTD at therapeutic doses. Look at EsoBiotec's ESO-T01 trial (NCT06791681). Every single patient developed grade 3+ adverse events. One died from immune effector cell-associated neurotoxicity. That's the kind of headline that kills a program. • Cell Specificity (off-targeting risk, LVV permanent insertion vs RNA transient approach): LVV permanent insertion carries lasting off-target editing risk. RNA transient platforms, using targeted LNPs, cut that risk and give you more control over specificity through ligand engineering. Ligand formats such as full antibodies, scFv, VHH nanobodies, peptides, and oligos sharpen cell specificity while trading off immunogenicity. • CAR Expression (LVV for blood cancer vs non-viral RNA-LNP for autoimmune): LVV-based platforms are taking over blood cancers, where sustained CAR expression is the priority. Non-viral RNA-LNP provides transient but strong expression for autoimmune conditions and immune reset, and its off-the-shelf manufacturability scales. The M&A wave tells you where the money went. Clinical data will tell you who got the biology right. 𝐅𝐨𝐫 𝐇𝐢𝐠𝐡-𝐑𝐞𝐬𝐨𝐥𝐮𝐭𝐢𝐨𝐧 𝐟𝐢𝐥𝐞 -If not connected, send a connection request and a note with written "PDF". -Otherwise, just comment "PDF"
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
125 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·9 min sitten · MuokattuYou're not the only one wondering what's coming in H1. Took a look at the ASGCT poster from May 2026 (see website) and see that in the last "box" "Conclusions" it states that in vivo studies of therapeutic potential in AAV9-circVec in 2 heart diseases were ongoing then. Danon disease which they started with in autumn 2025 and in Arrhythmogenic cardiomyopathy (ACM) is a rare, hereditary heart muscle disease where normal heart cells gradually die out and are replaced by scar tissue (fibrosis) and fat. The patient potential in the latter disease is large - estimated between 1.6 and 8 million patients. Imagine a treatment price of 1 million per patient and 250,000 patients gives revenue for this one disease alone of 250,000,000,000. Do you see the potential with circVec? New data from these projects should be expected in H1.
- ·3 t sitten · MuokattuThe world's first company with clinical trials in circular RNA was RiboX - started not long ago. Synthetic circularRNA (like Orna and Orbital etc.) - not DNA based like CircVec. They recently failed. A patient with an autoimmune disease has died after receiving an experimental genetic medicine from a biotech startup in China, Endpoints News has learned. The Shanghai-based company, RiboX Therapeutics, recently received a green light from the FDA to begin a clinical trial of the treatment in the US, which the company announced on Aug. 8. But RiboX did not publicly disclose the death in the earlier study until questioned by EndpointsSuper important for Circio! It automatically puts more pressure on Big Pharmas, which now indirectly must prioritize low dose/low toxicity even more. - Which Circio has, hello? 🥳💰
- ·4 t sittenI must say I'm really looking forward to the end of the month and the webcast. Circio and Wiklund have consistently impressed me with what is being presented. I believe and hope many will regret not buying more while they had the chance, but most of all, I think we can feel sorry for those who have sold out. Lots of luck to everyone! This will be an exciting period.
- ·4 t sitten · MuokattuA bit of CAR-T material from LinkedIn to shorten the waiting time and until we get CAR-T news going forward. The next 12-24 months will be important, he says. We know Circio is in the field but not acquired yet - the best trotters get a handicap - it's not important to be first at the start but to learn where others fail - the most important thing is to be best in the end. Cesare Di Nitto BD Manager @ Crystal NAX | Helped 200+ Biotech & Pharma advancing mRNA/LNP Programs | PhD Immuno-Oncology | Health, Fitness & Longevity 7 potential acquisitions. $17B+ committed. In vivo CAR-T is now a validated investment theme. We have seen it all: 1. AstraZeneca buying EsoBiotec ($1B, lentiviral ENaBL platform). 2. AbbVie taking Capstan Therapeutics ($2.1B, mRNA-LNP, Phase 1). 3. Gilead/Kite picked up Interius BioTherapeutics ($350M, integrating lentiviral vectors). 4. Bristol Myers Squibb grabbed Orbital Therapeutics ($1.5B for its circular RNA-LNP platform). 5. Eli Lilly and Company acquired Orna Therapeutics 1st ($2.4B, circRNA PAN-CAR LNP) 6. and Kelonia Therapeutics 2nd ($3.25B upfront, $7B total) 7. finally the recent Johnson & Johnson move to potentially acquire Sail Biomedicines ($785M upfront plus a $2.58B exclusive option, circRNA-tLNP). Pharma has made its conviction clear. But conviction isn't the same as clinical proof. The next 12-24 months will sort out who actually cracked it. Three things will separate the winners: • Safety Profile (MTD, toxicity): Genomic insertion is the risk RNA-LNP simply doesn't take on. No insertional mutagenesis. No long-term genotoxicity. LVV platforms carry both, and can hit MTD at therapeutic doses. Look at EsoBiotec's ESO-T01 trial (NCT06791681). Every single patient developed grade 3+ adverse events. One died from immune effector cell-associated neurotoxicity. That's the kind of headline that kills a program. • Cell Specificity (off-targeting risk, LVV permanent insertion vs RNA transient approach): LVV permanent insertion carries lasting off-target editing risk. RNA transient platforms, using targeted LNPs, cut that risk and give you more control over specificity through ligand engineering. Ligand formats such as full antibodies, scFv, VHH nanobodies, peptides, and oligos sharpen cell specificity while trading off immunogenicity. • CAR Expression (LVV for blood cancer vs non-viral RNA-LNP for autoimmune): LVV-based platforms are taking over blood cancers, where sustained CAR expression is the priority. Non-viral RNA-LNP provides transient but strong expression for autoimmune conditions and immune reset, and its off-the-shelf manufacturability scales. The M&A wave tells you where the money went. Clinical data will tell you who got the biology right. 𝐅𝐨𝐫 𝐇𝐢𝐠𝐡-𝐑𝐞𝐬𝐨𝐥𝐮𝐭𝐢𝐨𝐧 𝐟𝐢𝐥𝐞 -If not connected, send a connection request and a note with written "PDF". -Otherwise, just comment "PDF"
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
125 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·9 min sitten · MuokattuYou're not the only one wondering what's coming in H1. Took a look at the ASGCT poster from May 2026 (see website) and see that in the last "box" "Conclusions" it states that in vivo studies of therapeutic potential in AAV9-circVec in 2 heart diseases were ongoing then. Danon disease which they started with in autumn 2025 and in Arrhythmogenic cardiomyopathy (ACM) is a rare, hereditary heart muscle disease where normal heart cells gradually die out and are replaced by scar tissue (fibrosis) and fat. The patient potential in the latter disease is large - estimated between 1.6 and 8 million patients. Imagine a treatment price of 1 million per patient and 250,000 patients gives revenue for this one disease alone of 250,000,000,000. Do you see the potential with circVec? New data from these projects should be expected in H1.
- ·3 t sitten · MuokattuThe world's first company with clinical trials in circular RNA was RiboX - started not long ago. Synthetic circularRNA (like Orna and Orbital etc.) - not DNA based like CircVec. They recently failed. A patient with an autoimmune disease has died after receiving an experimental genetic medicine from a biotech startup in China, Endpoints News has learned. The Shanghai-based company, RiboX Therapeutics, recently received a green light from the FDA to begin a clinical trial of the treatment in the US, which the company announced on Aug. 8. But RiboX did not publicly disclose the death in the earlier study until questioned by EndpointsSuper important for Circio! It automatically puts more pressure on Big Pharmas, which now indirectly must prioritize low dose/low toxicity even more. - Which Circio has, hello? 🥳💰
- ·4 t sittenI must say I'm really looking forward to the end of the month and the webcast. Circio and Wiklund have consistently impressed me with what is being presented. I believe and hope many will regret not buying more while they had the chance, but most of all, I think we can feel sorry for those who have sold out. Lots of luck to everyone! This will be an exciting period.
- ·4 t sitten · MuokattuA bit of CAR-T material from LinkedIn to shorten the waiting time and until we get CAR-T news going forward. The next 12-24 months will be important, he says. We know Circio is in the field but not acquired yet - the best trotters get a handicap - it's not important to be first at the start but to learn where others fail - the most important thing is to be best in the end. Cesare Di Nitto BD Manager @ Crystal NAX | Helped 200+ Biotech & Pharma advancing mRNA/LNP Programs | PhD Immuno-Oncology | Health, Fitness & Longevity 7 potential acquisitions. $17B+ committed. In vivo CAR-T is now a validated investment theme. We have seen it all: 1. AstraZeneca buying EsoBiotec ($1B, lentiviral ENaBL platform). 2. AbbVie taking Capstan Therapeutics ($2.1B, mRNA-LNP, Phase 1). 3. Gilead/Kite picked up Interius BioTherapeutics ($350M, integrating lentiviral vectors). 4. Bristol Myers Squibb grabbed Orbital Therapeutics ($1.5B for its circular RNA-LNP platform). 5. Eli Lilly and Company acquired Orna Therapeutics 1st ($2.4B, circRNA PAN-CAR LNP) 6. and Kelonia Therapeutics 2nd ($3.25B upfront, $7B total) 7. finally the recent Johnson & Johnson move to potentially acquire Sail Biomedicines ($785M upfront plus a $2.58B exclusive option, circRNA-tLNP). Pharma has made its conviction clear. But conviction isn't the same as clinical proof. The next 12-24 months will sort out who actually cracked it. Three things will separate the winners: • Safety Profile (MTD, toxicity): Genomic insertion is the risk RNA-LNP simply doesn't take on. No insertional mutagenesis. No long-term genotoxicity. LVV platforms carry both, and can hit MTD at therapeutic doses. Look at EsoBiotec's ESO-T01 trial (NCT06791681). Every single patient developed grade 3+ adverse events. One died from immune effector cell-associated neurotoxicity. That's the kind of headline that kills a program. • Cell Specificity (off-targeting risk, LVV permanent insertion vs RNA transient approach): LVV permanent insertion carries lasting off-target editing risk. RNA transient platforms, using targeted LNPs, cut that risk and give you more control over specificity through ligand engineering. Ligand formats such as full antibodies, scFv, VHH nanobodies, peptides, and oligos sharpen cell specificity while trading off immunogenicity. • CAR Expression (LVV for blood cancer vs non-viral RNA-LNP for autoimmune): LVV-based platforms are taking over blood cancers, where sustained CAR expression is the priority. Non-viral RNA-LNP provides transient but strong expression for autoimmune conditions and immune reset, and its off-the-shelf manufacturability scales. The M&A wave tells you where the money went. Clinical data will tell you who got the biology right. 𝐅𝐨𝐫 𝐇𝐢𝐠𝐡-𝐑𝐞𝐬𝐨𝐥𝐮𝐭𝐢𝐨𝐧 𝐟𝐢𝐥𝐞 -If not connected, send a connection request and a note with written "PDF". -Otherwise, just comment "PDF"
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt